Key result
IV methylprednisolone pulsetherapy for severe rheumatic carditis shows a higher recent need for repeated treatment series.
Why the study?
Does IV methylprednisolone pulsetherapy improve outcomes in children with severe active rheumatic carditis?
Population
70 children with active rheumatic carditis (76 episodes) in heart failure Class III and IV (NYHA).
Design
Cohort
Follow-up
over 12 years (study period)
Authors
Loading...
Caution with rising recent treatment needs; leaves open evolving disease severity or resistance in rheumatic carditis.
Cohort (n=70)
Does IV methylprednisolone pulsetherapy improve outcomes in children with severe active rheumatic carditis?
High-dose IV methylprednisolone pulsetherapy remains a useful treatment protocol for severe active rheumatic carditis in children, despite variations in disease presentation over time.
Herdy et al. (1999) conducted a cohort in active rheumatic carditis (n=70). IV methylprednisolone pulsetherapy was evaluated on Need for 5 or more series of pulsetherapy. IV methylprednisolone pulsetherapy for severe rheumatic carditis showed variations in disease evolution over 12 years, with a significantly higher need for ≥5 treatment series in the recent group.